key: cord-0252397-a4e0kj5t
authors: Baghaei, Parvaneh; Nadji, Seyed Alireza; Marjani, Majid; Moniri, Afshin; Hashemian, Seyed Mohammadreza; Sheikhzade, Hakimeh; Abtahian, Zahra; Heshmatnia, Jalal; Abedini, Atefeh; Jamaati, Hamidreza; Mansourafshar, Babak; Ahmadi, Zargham Hossein; Mokhber Dezfuli, Mojtaba; Seifi, Sharareh; Sadeghi, Mohsen; Mirenayat, Maryam Sadat; Yassari, Fatemeh; Lookzadeh, Somayeh; Farzanegan, Behrooz; Kiani, Arda; Vasheghani, Maryam; Dastan, Farzaneh; Eslaminejad, Alireza; Malekmohammad, Majid; Varahram, Mohammad; Zali, Alireza; Tabarsi, Payam; Velayati, Ali Akbar
title: Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran
date: 2020-11-03
journal: Tanaffos
DOI: nan
sha: f270cb1ca5b62fe8be79b1024ec51eb12ca6616b
doc_id: 252397
cord_uid: a4e0kj5t

BACKGROUND: Following the recent epidemic of coronavirus disease 2019 (COVID-19) in Wuhan, China, a novel betacoronavirus was isolated from two patients in Iran on February 19, 2020. In this study, we aimed to determine the clinical manifestations and outcomes of the first confirmed cases of COVID-19 infection (n=127). MATERIALS AND METHODS: This prospective study was conducted on all COVID-19-suspected cases, admitted to Masih Daneshvari Hospital (a designated hospital for COVID-19), Tehran, Iran, since February 19, 2020. All patients were tested for COVID-19, using reverse transcription-polymerase chain reaction (RT-PCR) assay. Data of confirmed cases, including demographic characteristics, clinical features, and outcomes, were collected and compared between three groups of patients, requiring different types of admission (requiring ICU admission, admission to the general ward, and transfer to ICU). RESULTS: Of 412 suspected cases, with the mean age of 54.1 years (SD=13.4), 127 (31%) were positive for COVID-19. Following the patients’ first visit to the clinic, 115 cases were admitted to the general ward, while ten patients required ICU admission. Due to clinical deterioration in the condition of 25 patients (out of 115 patients), ICU admission was essential. Based on the results, the baseline characteristics of the groups were similar. Patients requiring ICU admission were more likely to have multiorgan involvement (liver involvement, P<0.001; renal involvement, P<0.001; and cardiac involvement, P=0.02), low O(2) saturation (P<0.001), and lymphopenia (P=0.05). During hospital admission, 21 (16.5%) patients died, while the rest (83.5%) were discharged and followed-up until March 26, 2020. Also, the survival rate of patients, who received immunoglobulin, was higher than other patients (60.87% vs. 39.13%). CONCLUSION: The mortality rate of COVID-19 patients was considerable in our study. Based on the present results, this infection can cause multiorgan damage. Therefore, intensive monitoring of these patients needs to be considered.

this study, we reported the first cases of laboratoryconfirmed COVID-19 (n=127), admitted to our center. showed that 43.55% of patients had lymphopenia (Table 1 and 

WHO. Coronavirus disease (COVID-2019) situation reports. 2020

Evaluation and Treatment Coronavirus

StatPearls [Internet

Home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak

Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Convalescent plasma as a potential therapy for COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics of and Important Lessons from the Coronavirus Disease

Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis

Coronaviruses post-SARS: update on replication and pathogenesis

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Effects of chloroquine on viral infections: an old drug against today's diseases?

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

First Case of 2019 Novel Coronavirus in the United States